Observational Prospective Study of Immune Checkpoint Inhibitors for Solid Neoplasms

Fudan University

Status: Enrolling

Conditions: Cancer

Study type: Observational

Funder types: Other

Identifiers

NCT04766515

ARION

Details and patient eligibility

About

This prospective, multicenter observational study included all patients with solid neoplasms who received treatment with immune checkpoint inhibitors (ICIs) in clinical practice, regardless of tumor type, tumor stage, type of immunotherapy, or treatment lines. This study aimed to assess the use, effectiveness, and safety of ICIs for solid neoplasms in real-world populations, which can provide insights into clinical decisions associated with the use of ICIs for the treatment of cancer patients in the real-world setting.

Enrollment: 2,000 estimated patients

Sex: All

Ages: 18+ years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Age at least 18 years.
• Pathologically confirmed diagnosis of a solid tumor cancer.
• Patients receiving treatment with immune checkpoint inhibitors.
• Ability to understand and willingness to provide the informed consent.

Exclusion criteria

• Age < 18 years.
• Patients with hematological malignancies or solid benign tumors.
• Mental disorders, drug abuse, and social condition that may negatively impact compliance in the opinion of the investigator.